SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: Qualified Opinion who wrote (3831)1/4/2003 12:54:24 AM
From: biostruggle  Respond to of 10345
 
Merril has estimated that skelaxin will go generic by June. Elan has significant protection for the 400 mg tablet, but in typical fashion they did not duplicate the fastings studies for their new 800 mg tablet. So the 800 mg maybe gone.